These projects were made possible from Cure Alzheimer's Fund support.
| Project Description | Researchers | Funding |
|---|---|---|
| General Scientific Support |
2023 $95,594 |
|
| Genes to Therapies (G2T), Alzheimer’s Disease Drug Discovery & Development (AD4) and General Scientific Support |
2022 $177,675 |
|
| Genes to Therapies™ (G2T), Alzheimer’s Disease Drug Discovery & Development (AD4), ACTFAST and General Scientific Support |
2021 $172,500 |
|
| Genes to Therapies (G2T) Centralized Research Core Oversight |
2014 to 2020 $1,233,640 |
These published papers resulted from Cure Alzheimer’s Fund support.
Suh, J., Romano, D. M., Nitschke, L., Herrick, S. P., DiMarzio, B. A., Dzhala, V., Bae, J. S., Oram, M. K., Zheng, Y., Hooli, B., Mullin, K., Gennarino, V. A., Wasco, W., Schmahmann, J. D., Albers, M. W., Zoghbi, H. Y., & Tanzi, R. E. Loss of Ataxin-1 Potentiates Alzheimer’s Pathogenesis by Elevating Cerebral BACE1 Transcription, Cell, August 22, 2019, Read More
Li, A., Ahsen, O. O., Liu, J. J., Du, C., McKee, M. L., Yang, Y., Wasco, W., Newton-Cheh, C. H., O'Donnell, C. J., Fujimoto, J. G., Zhou, C., & Tanzi, R. E. Silencing of the Drosophila ortholog of SOX5 in heart leads to cardiac dysfunction as detected by optical coherence tomography, Human Molecular Genetics, May 21, 2013, Read More
